Neuromedicine
Natural Complexes Are More Effective in Neuroprotection than Single Antioxidants
Download PDF (308.4 KB) PP. 1 - 8 Pub. Date: November 3, 2018
Author(s)
- Sergei A. Talanov
Department of Blood Circulation Physiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine - Vladimir A. Maisky
Department of Brain Physiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine - Olena A. Fedorenko*
Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK
Abstract
Keywords
References
[1] C.C. Chiueh, G. Krishna, P. Tulsi, T. Obata, K. Lang, S.J. Huang, and D.L. Murphy, “Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effect of MPP+,” Free Rad. Biol. Med., 13, 581-583, 1992.
[2] A. Napolitano, P. Manini, and M. d'Ischia, “Oxidation chemistry of catecholamines and neuronal degeneration: an update,” Curr. Med. Chem., 18, 1832-1845, 2011.
[3] P. Jenner, “Oxidative stress in Parkinson's disease,” Ann. Neurol., 53, 26-36, 2003.
[4] Y. Aluf, J. Vaya, S. Khatib, Y. Loboda, S. Kizhner, and J.P. Finberg, “Specific oxidative stress profile associated with partial striatal dopaminergic depletion by 6-hydroxydopamine as assessed by a novel multifunctional marker molecule,” Free Radic. Res., 44, 635-644, 2010.
[5] J. Han, F.C Cheng, Z. Yang, and G. Dryhurst, “Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implication to Parkinson's disease,” J. Neurochem., 73, 1683-1695, 1999.
[6] J.W. Langston, “MPTP neurotoxity: an overview and characterization of phases of toxicity,” Life Science, 36, 201-206, 1985.
[7] P. Foley, and P. Riederer, “Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease,” J. Neurol., 247 (S2), 82-94, 2000.
[8] V.F. Sagach, O.V. Bazilyuk, N.N. Oleshko, V.A. Maisky, A. Costa, and E. Martignoni, “Mesostriatal lesions and endothelial fumction: effects of forced movements and hypoxia on levels of circulating endothelins,” Neurophysiology 30, 18-24, 1998.
[9] V.A. Maisky, N.N. Oleshko, O.V. Bazilyuk, S.A. Talanov, V.F. Sagach, and O. Appenzeller, “Fos and nitric oxide synthase in rat brain with chronic mesostriatal dopamine deficiency: effects of nitroglycerin and hypoxia,” Parkinsonism Relat. Disord., 8, 261-270, 2002.
[10] H.C. Curtius, M. Wolfensberger, B. Steinmann, U. Redweik, and J. Siegfried, “Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus,” J. Chromatography, 99, 529-540, 1974.
[11] R. Andrew, D.G. Watson, S.A. Best, J.M. Midgley, H. Wenlong, and R.K. Petty, “The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls,” Neurochem. Res., 18, 1175-1177, 1993.
[12] J.C. Mayo, R.M. Sainz, H. Uria, I. Antolin, M.M. Esteban, and C. Rodriguez, “Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease,” J. Pineal. Res. 3, 179-192, 1998.
[13] U. Ungerstedt, “Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system,” Acta Physiol. Scand., 367, 95-122, 1997.
[14] S.A. Talanov, N.N. Oleshko, M.N. Tkachenko, and V.F. Sagach, “Pharmacoprotective influences on different links of the mechanism underlying 6-hydroxydopamine-induced degeneration of nigrostriatal dopaminergic neurons,” Neurophysiology, 38, 128-133, 2006.
[15] L.T. Pellegrino, A.S. Pellegrino, and A.T. Cushman, “A stereotaxic atlas of the rat brain,” New York: Plenum Press, 1979.
[16] D. Kirik, C. Rosenblad, and A. Bj?rklund, “Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat,” Exp. Neurol., 152, 259-277, 1998.
[17] G. Paxinos, and C. Watson, “The rat brain in stereotaxic coordinated,” New York: Academic Press, 1997.
[18] F.L. Crane, “Biochemical functions of coenzyme Q10,” J. Am. Coll. Nutr., 20, 591-598, 2001.
[19] I.P. Hargreaves, A. Lane, and P.M. Sleiman, “The coenzyme Q10 status of the brain regions of Parkinson's disease patients,” Neurosci. Lett., 447, 17-19, 2008.
[20] R. Ricciarelli, F. Argellati, M.A. Pronzato, and C. Domenicotti, “Vitamin E and neurodegenerative diseases,” Mol. Aspects Med., 28, 591-606, 2007.
[21] A. Azzi, E. Aratri, D. Boscoboinik, S. Clément, N.K. Ozer, R. Ricciarelli, and S. Spycher, “Molecular basis of alpha-tocopherol control of smooth muscle cell proliferation,” Biofactors, 7, 3-14, 1998.
[22] D.A. Butterfield, A. Castegna, J. Drake, G. Scapagnini, and V. Calabrese, “Vitamin E and neurodegenerative disorders associated with oxidative stress,” Nutr. Neurosci., 5, 229-239, 2002.
[23] V.F. Sagach, M. Scrosati, J. Fielding, G. Rossoni, C. Galli, and F.Visioli, “The water-soluble vitamin E analogue Trolox protects against ischaemia/reperfusion damage in vitro and ex vivo. A comparison with vitamin E,”Pharmacol. Res., 45, 435-439, 2002.
[24] S.C. Bondy, and E.H. Sharman, “Melatonin and the aging brain,” Neurochem. Int., 50, 571-580, 2007.
[25] E.H. Sharman, S.C. Bondy, K.G. Sharman, D. Lahiri, C.W. Cotman, and V.M. Perreau, “Effects of melatonin and age on gene expression in mouse CNS using microarray analysis,” Neurochem. Int., 50, 336-344, 2007.
[26] S.C. Bondy, H. Li, J. Zhou, M. Wu, J.A. Bailey, and D.K. Lahiri, “Melatonin alters age-related changes in transcription factors and kinase activation,” Neurochem. Res., 35, 2035-2042, 2010.
[27] S.L. Albarracin, B. Stab, Z. Casas, J.J. Sutachan, I. Samudio, J. Gonzalez, L. Gonzalo, F. Capani, L.Morales, and G.E. Barreto, “Effects of natural antioxidants in neurodegenerative disease,” Nutr. Neurosci., 15, 1-9, 2012.
[28] B. Zhao, “Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease,” Neurochem. Res., 34, 630-638, 2009.